AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

KNSA · NASDAQ · Medical - Pharmaceuticals

Kiniksa Pharmaceuticals (KNSA)

Markets ARCALYST for recurrent pericarditis while advancing a cardiovascular-focused clinical pipeline.

$80.10

Pre-market+0.17 (+0.21%)

At close$79.93(+0.82%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	67	83	80	109	112	123	138	157	181	202	214	244
Cost of revenue	27	27	32	42	49	66	62	71	84	91	96	112
Gross profit	40	57	48	66	63	56	76	86	97	111	118	132
	51	57	65	66	72	76	63	66	73	91	89	105
Research & development	17	20	26	24	26	35	19	19	24	35	27	41
	34	37	39	42	46	41	44	47	49	57	61	64
General & administrative	0	0	0	0	0	0	0	0	0	0	0	64
Operating income	−11	0	−17	0	−10	−19	13	20	24	20	29	27
	2	2	2	2	2	2	2	3	3	4	3	4
Interest income	2	2	0	2	2	2	2	3	3	3	3	4
Interest expense	0	2	0	0	0	0	0	0	0	0	0	0
Other non-operating income	−2	−2	−2	−2	−2	−2	−2	−3	−3	−4	−3	0
Income before tax	−8	2	−14	2	−7	−17	16	23	27	23	33	31
Income tax expense	5	−23	3	6	5	−8	7	5	9	9	10	6
Net income from continuing operations	−14	25	−18	−4	−13	−9	9	18	18	14	23	25
Net income	−14	25	−18	−4	−13	−9	9	18	18	14	23	25
EPS, basic	−$0.20	$0.36	−$0.25	−$0.06	−$0.18	−$0.12	$0.12	$0.24	$0.25	$0.19	$0.30	$0.33
EPS, diluted	−$0.20	$0.35	−$0.25	−$0.06	−$0.18	−$0.12	$0.11	$0.23	$0.23	$0.18	$0.27	$0.30
Weighted average shares, basic	70	70	71	71	72	72	73	73	74	74	77	78
Weighted average shares, diluted	70	73	71	71	72	72	76	78	78	79	82	83
EBITDA	−8	3	−14	3	−7	−17	16	23	28	24	33	28
Depreciation & amortization	1	0	0	0	0	0	0	0	0	0	0	0
EBIT	−8	2	−14	2	−7	−17	16	23	27	23	33	27